Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | LGMN | Q99538 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 4/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | INSR | P06213 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3345453 | 1.00 | NTSR1 (0.43) | NTSR1ALDH1A1CYP3A4TSHRHSD17B10 | |
| SCHEMBL30682434 | 1.00 | NTSR1 (0.43) | NTSR1ALDH1A1CYP3A4TSHRHSD17B10 | |
| SCHEMBL10205069 | 0.92 | ALK (0.43) | NTSR1ALDH1A1LGMNCHEK1SUV39H2 | |
| SCHEMBL5406594 | 0.91 | DPP4 (0.46) | NTSR1ALDH1A1CYP3A4TSHRHSD17B10 | |
| Hydrochloric Acid SCHEMBL5387731 | 0.90 | DPP4 (0.45) | NTSR1ALDH1A1CYP3A4SUV39H2DPP4 | |
| SCHEMBL24073829 | 0.88 | CHEK1 (0.46) | NTSR1ALDH1A1CYP3A4LGMNCHEK1 | |
| SCHEMBL17265199 | 0.88 | ALDH1A1 (0.46) | ALDH1A1CYP3A4TSHRHSD17B10TDP1 | |
| SCHEMBL520117 | 0.87 | SLC6A4 (0.40) | NTSR1LGMNSUV39H2DPP4PDE7A | |
| SCHEMBL519205 | 0.87 | SLC6A4 (0.40) | NTSR1LGMNSUV39H2DPP4PDE7A | |
| SCHEMBL519204 | 0.87 | SLC6A4 (0.40) | NTSR1LGMNSUV39H2DPP4PDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109516977-B | Anilinopyrimidine/quinoline heterocomplex, preparation method and medical application | 长治学院 | 2020-01-10 | — | — | CN | claimed |
| CN-117003703-A | 2- (2- (4-secondary amine substituted anilino) pyrimidin-4-yl) aminobenzoate or amide derivative and application thereof | 长治学院 | 2023-11-07 | — | — | CN | disclosed |
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-10-05 | — | — | US | disclosed |
| WO-2022257732-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINE DERIVATIVES AND APPLICATION THEREOF | 腾讯科技（深圳）有限公司 | 2022-12-15 | — | — | WO | disclosed |
| WO-2021238827-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | 南京红云生物科技有限公司 | 2021-12-02 | — | — | WO | disclosed |
| EP-3372594-B1 | PYRIMIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | HUMANWELL HEALTHCARE GROUP CO LTD (CN) | 2021-07-21 | — | — | EP | disclosed |
| US-10695347-B2 | Pyrimidine derivative and use thereof | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) | 2020-06-30 | — | — | US | disclosed |
| US-10611765-B2 | Pyrrolopyrimidine derivatives as Mps1/TTK kinase inhibitors | OHIO STATE INNOVATION FOUNDATION | 2020-04-07 | — | — | US | disclosed |
| US-10611765-B2 | Pyrrolopyrimidine derivatives as Mps1/TTK kinase inhibitors | OHIO STATE INNOVATION FOUNDATION | 2020-04-07 | — | — | US | disclosed |
| WO-2009032694-A1 | AMINO SUBSTITUTED PYRIMIDINE, PYROLLOPYRIDINE AND PYRAZOLOPYRIMIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS AND IN TREATING PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | DANA FARBER CANCER INSTITUTE (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009020990-A1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) AMINO] BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | SMITHKLINE BEECHAM CORPORATION (US) | 2009-02-12 | — | — | WO | disclosed |
| WO-2009020990-A1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) AMINO] BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | SMITHKLINE BEECHAM CORPORATION (US) | 2009-02-12 | — | — | WO | disclosed |
| WO-2008150799-A1 | IMIDAZOPYRIDINE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008150799-A1 | IMIDAZOPYRIDINE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | ABL1, MAP3K19, MAP3K5 | NTSR1 2182/4885ALDH1A1 3410/4885CYP3A4 1025/4885 |
| US-10695347-B2 | Pyrimidine derivative and use thereof | ALK, DPYD, TYMP | NTSR1 2523/4885ALDH1A1 252/4885CYP3A4 602/4885 |
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, ERBB4 | NTSR1 2386/4885ALDH1A1 3822/4885CYP3A4 1058/4885 |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | TYMS, TYMP, DPYD | NTSR1 3842/4885ALDH1A1 647/4885CYP3A4 555/4885 |
| US-10611765-B2 | Pyrrolopyrimidine derivatives as Mps1/TTK kinase inhibitors | TTBK1, TTK, TTBK2 | NTSR1 2811/4885ALDH1A1 3510/4885CYP3A4 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.